MX2019010732A - Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. - Google Patents
Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.Info
- Publication number
- MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A
- Authority
- MX
- Mexico
- Prior art keywords
- catecholamine
- cst
- tumors
- cushing
- bind
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 150000003943 catecholamines Chemical class 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000003248 secreting effect Effects 0.000 title abstract 2
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 5
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 5
- 102000003998 progesterone receptors Human genes 0.000 abstract 4
- 108090000468 progesterone receptors Proteins 0.000 abstract 4
- 208000014311 Cushing syndrome Diseases 0.000 abstract 3
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 2
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000011349 peptide receptor radionuclide therapy Methods 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hematology (AREA)
- Obesity (AREA)
Abstract
Se describen novedosos métodos para tratar tumores, que incluyen tumores neuroendocrinos (NET), tal como un tumor secretor de catecolamina (CST). Los métodos incluyen síndrome de Cushing en un paciente con síndrome de Cushing que tiene un NET, tal como un CST. Los tumores pueden ser tratados con un modulador de receptor de glucocorticoide (GR) (GRM), tal como un antagonista de GR (GRA). Los novedosos tratamientos pueden tratar síndrome de Cushing, pueden reducir la producción de catecolamina por el tumor, pueden reducir el exceso de catecolamina, pueden mejorar los síntomas de exceso de catecolamina y pueden mejorar la eficacia de bloqueo a- o ß-adrenérgico, tratamiento o imagenología con somatostatina o análogo de somatostatina, o terapia de radionúclido de receptor de péptido, en pacientes con un CST. El GRM puede reducir la activación de un GR y pueden unirse a un GR con mayor afinidad que con la que se une a un receptor de progesterona (PR). En modalidades, el fármaco puede unirse solo pobremente a PR y puede no unirse de manera medible a PR.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469296P | 2017-03-09 | 2017-03-09 | |
| PCT/US2018/021592 WO2018165460A1 (en) | 2017-03-09 | 2018-03-08 | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010732A true MX2019010732A (es) | 2019-11-01 |
Family
ID=63446773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010732A MX2019010732A (es) | 2017-03-09 | 2018-03-08 | Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11045482B2 (es) |
| EP (1) | EP3592358A4 (es) |
| JP (3) | JP7564620B2 (es) |
| CN (1) | CN110475558A (es) |
| AU (1) | AU2018230429B2 (es) |
| CA (1) | CA3053806A1 (es) |
| MX (1) | MX2019010732A (es) |
| WO (1) | WO2018165460A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7444889B2 (ja) * | 2018-12-20 | 2024-03-06 | コーセプト セラピューティクス， インコーポレイテッド | ソマトスタチン受容体陽性腫瘍のイメージング及び治療のための方法 |
| JP2021079146A (ja) * | 2021-02-22 | 2021-05-27 | 株式会社三洋物産 | 遊技機 |
| JP7315071B2 (ja) * | 2021-03-03 | 2023-07-26 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
| CA2246791A1 (en) | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
| US6818739B2 (en) | 1999-12-03 | 2004-11-16 | Ndsu Research Foundation | Somatostatins |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| PT1370268E (pt) * | 2001-03-23 | 2009-08-26 | Corcept Therapeutics Inc | Métodos de tratamento de perturbações de stress usando antagonistas específicos dos receptores de glucocorticóides |
| WO2003057214A1 (en) | 2001-12-28 | 2003-07-17 | Somatocor Pharmaceuticals, Inc. | Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands |
| CN101027301B (zh) | 2004-03-09 | 2011-06-29 | 科塞普特治疗公司 | 稠环氮杂十氢化萘糖皮质激素受体调节剂 |
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| US20100178663A1 (en) * | 2007-05-15 | 2010-07-15 | Waters Technologies Corporation | Apparatus And Methods For The Detection Of Plasma Metanephrines |
| WO2009050136A2 (en) * | 2007-10-17 | 2009-04-23 | Laboratoire Hra Pharma | Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome |
| ES2351569B8 (es) | 2009-05-07 | 2012-06-20 | Bcn Peptides S.A. | Ligandos peptídicos de receptores de somatostatina. |
| US8461172B2 (en) | 2009-05-12 | 2013-06-11 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| US10071030B2 (en) * | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| SG193509A1 (en) | 2011-03-18 | 2013-10-30 | Corcept Therapeutics Inc | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2013039916A1 (en) * | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| MY180141A (en) | 2013-11-25 | 2020-11-23 | Corcept Therapeutics Inc | Octahydro fused azadecalin glucocorticoid receptor modulators |
| CN107530435A (zh) * | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
| US9943526B2 (en) * | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
-
2018
- 2018-03-08 MX MX2019010732A patent/MX2019010732A/es unknown
- 2018-03-08 WO PCT/US2018/021592 patent/WO2018165460A1/en not_active Ceased
- 2018-03-08 AU AU2018230429A patent/AU2018230429B2/en active Active
- 2018-03-08 US US15/915,284 patent/US11045482B2/en active Active
- 2018-03-08 EP EP18763240.1A patent/EP3592358A4/en active Pending
- 2018-03-08 CN CN201880015928.3A patent/CN110475558A/zh active Pending
- 2018-03-08 CA CA3053806A patent/CA3053806A1/en active Pending
- 2018-03-08 JP JP2019548370A patent/JP7564620B2/ja active Active
-
2022
- 2022-04-21 JP JP2022070027A patent/JP2022090003A/ja not_active Withdrawn
-
2024
- 2024-03-28 JP JP2024053332A patent/JP2024074854A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3592358A1 (en) | 2020-01-15 |
| CA3053806A1 (en) | 2018-09-13 |
| JP2020510011A (ja) | 2020-04-02 |
| AU2018230429B2 (en) | 2023-06-15 |
| US11045482B2 (en) | 2021-06-29 |
| JP2022090003A (ja) | 2022-06-16 |
| WO2018165460A1 (en) | 2018-09-13 |
| AU2018230429A1 (en) | 2019-09-05 |
| JP2024074854A (ja) | 2024-05-31 |
| US20180256604A1 (en) | 2018-09-13 |
| EP3592358A4 (en) | 2020-12-16 |
| JP7564620B2 (ja) | 2024-10-09 |
| CN110475558A (zh) | 2019-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| WO2016187220A3 (en) | Anti-ror1 antibodies | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| GB2454118A (en) | Hdac inhibitors and hormone targeted drugs for the treatment of cancer | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| MY199903A (en) | Combination therapy with controlled-release cnp agonists | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| PL2288413T3 (pl) | Urządzenie terapeutyczne łączące radioterapię z termoterapią | |
| MX2019010732A (es) | Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| WO2019118779A3 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| MX2019003751A (es) | Proteina terapeutica. | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia |